ABBVIE
 
公司簡況
財務
派息紀錄
盈利預測
股權變動
ETF簡況
 
 
 
公司概覽
業務類別 Drug Manufacturers - General
業務概覽 AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan addedseveral new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
公司地址 1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
電話號碼 +1 847 932-7900
傳真號碼 --
公司網頁 https://www.abbvie.com
員工數量 57000
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Mr. David R. Purdue Principal Accounting Officer, Senior Vice President and Controller -- 20/02/2026
Mr. Demetris D. Crum Executive Vice President and Chief Human Resources Officer -- 20/02/2026
Dr. Roopal Thakkar, M.D. Executive Vice President, Research and Development and Chief Scientific Officer 美元 1.15M 20/02/2026
Dr. Azita Saleki-Gerhardt, B.S.,M.S.,PhD Executive Vice President and Chief Operations Officer 美元 1.05M 20/02/2026
Dr. Nicholas J. Donoghoe, M.D. Executive Vice President, Chief Business and Strategy Officer -- 20/02/2026
Mr. Robert A. Michael Chairman of the Board and Chief Executive Officer 美元 1.70M 23/03/2026
Mr. Jeffrey Ryan Stewart Executive Vice President and Chief Commercial Officer 美元 1.32M 20/02/2026
Mr. Scott T. Reents Executive Vice President and Chief Financial Officer 美元 1.12M 20/02/2026
Mr. Perry C. Siatis Executive Vice President, General Counsel and Secretary -- 20/02/2026
 
董事會成員
董事會 職務 更新日期
Mr. Frederick H. Waddell Independent Director 23/03/2026
Ms. Rebecca B. Roberts Independent Director 23/03/2026
Dr. Robert J. Alpern,M.D. Independent Director 23/03/2026
Mr. Thomas C. Freyman Independent Director 23/03/2026
Mr. Edward J. Rapp Independent Director 23/03/2026
Dr. Susan E. Quaggin, M.D. Independent Director 23/03/2026
Ms. Roxanne S. Austin Lead Independent Director 23/03/2026
Mr. Brett J. Hart Independent Director 23/03/2026
Mr. William H.L. Burnside Independent Director 23/03/2026
Ms. Melody B. Meyer Independent Director 23/03/2026
Mr. Robert A. Michael Chairman of the Board and Chief Executive Officer 23/03/2026
Mr. Thomas J. Falk Independent Director 23/03/2026
Ms. Jennifer L. Davis Independent Director 23/03/2026
 
所屬ETF (更新日期: 02/05/2026 04:23)
代號 名稱 佔比% ▼ 持有日期
SPXTProShares S&P 500® ex-Technology0.001%29/04/2026
AVTMAvantis Total Equity Markets ETF0.001%29/04/2026
AGNGGlobal X Aging Population ETF0.001%29/04/2026
FLCCFederated Hermes MDT Large Cap Core ETF0.001%29/04/2026
BRESBurney U.S. Equity Select ETF0.001%29/04/2026
CRTCXtrackers US National Crtcl Techs ETF0.001%29/04/2026
AAUAAlpha Architect US Equity 3 ETF0.001%10/04/2026
FTXHFirst Trust Nasdaq Pharmaceuticals ETF0.001%29/04/2026
RJDIRJ Eagle GCM Dividend Select Income ETF0.001%29/04/2026
FUNLCornerCap Fundametrics® Lrg-Cap ETF FUNL0.001%02/03/2026
ACVUHartford Alpha Capture Value ETF0.001%29/04/2026
IGAVoya Global Advantage and Premium Opp0.001%31/03/2026
ROEAstoria US Equal Weight Quality KingsETF0.001%29/04/2026
PBPInvesco S&P 500 BuyWrite ETF0.001%29/04/2026
BDVLiShares Disciplined Vol Eq Act ETF0.001%10/04/2026
USNZXtrackers Net Zero Pwy Par Alg US Eq ETF0.001%29/04/2026
PFDEPathfinder Disciplined US Equity ETF0.001%29/04/2026
RAFEPIMCO RAFI ESG US ETF0.001%27/04/2026
PAPIParametric Equity Premium Income ETF0.001%29/04/2026
AFLGFirst Trust Active Factor Large Cap ETF0.001%29/04/2026
  1    2    3    4    5    6    7    8    9    10    11    12   13    14    15    16    17    18    19    20    21    22    23    24    25    26    27    28    29  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.